ContextVision AB: Transactions made under the buy-back programme
Oslo, 23 Oktober – On 3 September, ContextVision AB (“ContextVision” or the “Company”) announced a share buy-back programme of up to NOK 10,000,000, with a maximum of 4,000,000 shares, in the period from 5 September 2025 to 5 March 2026.
DNB Carnegie, acting under the mandate from ContextVision, has carried out the following transactions under the buy-back programme:
| Date | Aggregated daily volume (number of shares) | Weighted average share price per day (NOK) | Total daily transaction value (NOK) |
| 2025-10-15 | 12 072 | 4,4694 | 54 035,48 |
| 2025-10-16 | 11 999 | 4,5000 | 53 995,50 |
| 2025-10-17 | 7 554 | 4,4300 | 34 030,77 |
| 2025-10-20 | 5 212 | 4,5253 | 23 585,86 |
| 2025-10-21 | 8 271 | 4,4511 | 36 859,71 |
| 2025-10-22 | 7 244 | 4,4285 | 32 093,09 |
| 2025-10-23 | 11 664 | 4,4540 | 51 854,64 |
| Previously disclosed buy-buys under the programme (accumulated) | 304 633 | 4,5437 | 1 386 282,42 |
| Accumulated under the buy-back programme | 368 649 | 4,5284 | 1 672 737,48 |
Following the completion of the above transactions, ContextVision owns a total of 1 746 811 of own shares, corresponding to 2.26% of ContextVision’s share capital.
An overview of all transactions made under the buy-back programme that have been carried out during the abovementioned time period is attached to this report and available at www.newsweb.no.
For further information, please contact:
Richard Hallström, CFO
Email: richard.hallstrom@contextvision.com
About ContextVision AB:
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.